Back to today’s briefing

Story perspectives

Study Reveals ctDNA Changes Predict mRCC Patient Outcomes

5/7/2025

42 10

Summary

Story summary

In a groundbreaking study on metastatic renal cell carcinoma (mRCC), researchers found that changes in circulating tumor DNA (ctDNA) are tied to worse patient outcomes. Those with multiple ctDNA alterations faced shorter progression-free survival. This analysis highlights ctDNA profiling as a powerful tool for predicting clinical outcomes and uncovering new treatment targets, surpassing traditional tissue methods.

1 of 1

Story summary

In a groundbreaking study on metastatic renal cell carcinoma (mRCC), researchers found that changes in circulating tumor DNA (ctDNA) are tied to worse patient outcomes. Those with multiple ctDNA alterations faced shorter progression-free survival. This analysis highlights ctDNA profiling as a powerful tool for predicting clinical outcomes and uncovering new treatment targets, surpassing traditional tissue methods.